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INTRODUCTION 
General aspects: 
Small-cell lung cancer (SCLC) accounts for about 15% of all lung cancer cases and is 
associated with a history of heavy tobacco smoking (1). The incidence of SCLC has 
continuously declined in the last decades because of intensive onset of tobacco cessation 
programs. However, the prognosis of patients with SCLC remains very poor due to 
propensity for early dissemination, first of all to the brain (1, 2). 
SCLC is typical for patients aged > 60 years. At initial presentation, symptomatic bulky 
tumor accompanying with extensive lymph node involvement is common. In 75 - 80% of 
patients at initial diagnosis, metastatic spread to different organs will be found. Multiple 
brain metastases (BM) are detected in up to 25% of patients at diagnosis; at least half of 
them will be occult and detected within the scope of initial tumor staging (2, 3). 
 
Histology: 
Morphologically rapidly proliferating small cells with a high nucleo-cytoplasmic ratio and 
neurosecretory granules are typical for SCLC (2, 4). There are several histological and 
immunohistochemical markers which were shown to be characteristic for this type of 
tumor. They include transcription thyroid factor-1 (positive in more than 85% of patients); 
cytokeratin 7; chromogranin A and synaptophysin. Additionally, myc amplification and 
p53 mutation was described in approximately 75% of patients. Deletions of known tumor-
suppressor genes (TP53 and RB1) are also typical. However, targeted driver mutations 
described for the non-small cell lung cancer (EGFR-, ALK-, ROS1-, BRAF-, RET- etc.) 
are extremely rare in SCLC (4). 
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Tumor Classification and Staging:  
Since 2009 tumor-node-metastasis (TNM) classification has been proposed for SCLC (1, 
2, 4, 5). Use of TNM classification is obligatory and will help clinicians to better assess 
the risk categories and prognostic factors of disease as well as personalize multimodal 
treatment. However, the absolute majority of institutions continuously use a simplified 
two-stage system which was developed by the Veterans Administration Lung Cancer 
Group. This old classification categorized SCLC tumor burden as limited (LD) or 
extensive (ED) disease. LD is defined as disease which is limited to one hemithorax with 
or without contralateral hilar and supraclavicular lymph node involvement. Pleural and 
pericardial effusion was excluded from LD.  
An initial tumor staging in SCLC consists of contrast-enhanced computed tomographic 
(CT) scans of the neck, chest and abdomen, bone scintigraphy and a contrast-enhanced 
magnetic resonance image (MRI) or CT of the brain. The whole body 18F-FDG-PET/CT 
scan is also widely used as an initial staging tool. In this case a bone scan can be 
potentially omitted. 
 
Treatment standards and prognosis 
There are different treatment standards for LD and ED (1, 2, 4, 5). LD SCLC is a 
potentially curative disease. In general, treatment is always multimodal and depends on 
TNM Stage and patient performance status. In case of very limited disease (T1-2 tumors 
without mediastinal lymph node involvement) radical surgery consisting of lobectomy and 
regional lymph node dissection could be considered (6). For the absolute majority of 
patients platinum-based concurrent and/or sequential chemoradiotherapy (CRT) is an 
actual treatment standard. The landmark randomized  
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trials on this topic have shown that the best historical survival rates could be achieved  
with early (first chemotherapy cycle) concurrent hyperfractionated accelerated 
platinumbased CRT according to Turrisi et al. (7). After surgery and/or definitive CRT and 
in the case of intrathoracic treatment response, prophylactic cranial irradiation (PCI) 
should be delivered. 
In case of ED, a platinum-based chemotherapy with 4 to maximal 6 cycles is a 
cornerstone of treatment. In the case of treatment response, consolidative thoracic 
irradiation and PCI are recommended to significantly reduce the rate of the loco-regional 
and intracranial failure. 
In general practice, median overall survival and 5-year survival rates in metastatic (ED) 
and non-metastatic (LD) SCLC reached 9 to 12 and 15 to 25 months as well as 0-5 and 
10-25%, respectively (1, 2, 4). In both non- and metastatic disease, there is a stagnation 
of real-life patient survival in the last two decades (2, 4). In spite of continuous clinical 
research, no significant improvement of patient prognosis could be achieved. According 
to prospective trials dedicated to primary multimodal treatment in SCLC, there is actually 
no benefit of chemotherapy intensification and consolidation. Also, the clinical results of 
targeted therapy remain disappointing.  
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RESEARCH BACKGROUND 
In spite of progress in the development of new chemo- and targeted therapy agents as 
well as technical improvement of radiation delivery, the prognosis of patients with non-
metastatic SCLC is still disappointing (2, 4). A marginal survival benefit achieved in the 
last decade is mostly due to significant improvement of the initial tumor staging: 
consecutive use of TNM classification and integration of comprehensive intra- and 
extracranial diagnostic procedures. However, there was no relevant progress, regarding 
the primary multimodal treatment itself. For many years, there has been ongoing debate 
concerning optimal patient-directed application of chemotherapy and thoracic as well as 
cranial irradiation. 
According to the landmark randomized trials, primary CRT is a keystone treatment for LD 
SCLC (7 – 14). This multimodal treatment approach consists of the two primary 
modalities: chemotherapy and the loco-regional thoracic irradiation. Because of 
significant risk for the circulating tumor cells, micro-metastatic disease as well as early 
and rapid systemic dissemination, chemotherapy remains a cornerstone of treatment. 
However, an extremely high rate (50 to 90% in the first and second year after diagnosis, 
respectively) of post-chemotherapy intra-thoracic recurrences was a reason for the 
integration of the loco-regional radiotherapy as a consolidation treatment for primary 
thoracic disease (8 – 9). Three mostly considerable factors concerning thoracic irradiation 
in LD SCLC are application type (concurrent versus sequential), prescription of the 
radiation dose (hyperfractionated accelerated versus conventional) and timing (early 
versus late). All these factors have been the subject of randomized trials the last thirty 
years. Some of them have documented survival benefit for concurrent multimodal 
treatment (10 - 11), others have not (12 - 13). The results of the trials which directly  
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compared early versus late concurrent CRT were also diverse (14 – 18). Furthermore, 
relevant differences between trials regarding the initial tumor staging and the dose 
density of chemotherapy and thoracic irradiation are the most important critical points. 
Several meta-analyses have revealed a significant survival benefit for early platinum-
based concurrent CRT with overall treatment time of thoracic irradiation less than 30 days 
(19 - 22). A short time between the first day of chemotherapy and the last day of thoracic 
irradiation was also associated with improved long-term outcome. The start of any 
treatment until the end of radiotherapy (SER) as a timing parameter was proposed as a 
prognostic parameter with a shorter SER (less than 30 days) as pre-requisite for 5-year 
survival rates greater than 20% (22). The latest meta-analysis on this topic consisted of 
nine randomized trials and individual data from 2305 LD SCLC patients (23). Moreover, 
only randomized trials comparing early vs. late timing schedules of curative thoracic 
irradiation together with chemotherapy were included. Importantly, early radiotherapy 
was defined as treatment starting before the third chemotherapy cycle or nine weeks after 
randomization. All patients were divided into two arms: “earlier or shorter” and “later or 
longer”. There were no significant differences regarding patient characteristics in both 
arms. Principally, the study could not find any positive survival effect of the “earlier or 
shorter” versus “later or longer” thoracic irradiation. However, subsequent subgroup 
analysis revealed a significant survival benefit in favour of “earlier or shorter” radiotherapy 
when similar and higher chemotherapy compliance was reached and in favour of “later 
or longer” radiotherapy when chemotherapy compliance was different and poor. This was 
the first time a significant association of treatment and/or patient compliance and 
treatment effect was documented in LD SCLC. 
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Another relevant treatment-related aspect in this field is universal adoption of early 
concurrent platinum-based hyperfractionated accelerated CRT analogueTurrisi et al in 
clinical routine (24, 25). Although best historical survival rates have been achieved with 
Turrisi protocol, the adoption rate of this early concurrent treatment, unfortunately, 
remains low and depends significantly on geographic region and treatment center 
(academic vs non-academic). Additionally, the highly-awaited phase III trial (CONVERT) 
was published last year and demonstrated non-significant differences in outcomes with 
hyperfractionated accelerated versus conventional concurrent CRT, starting both with the 
second chemotherapy cycle (median overall survival of 30 versus 25 months (HR 1.18, 
95% CI 0.95–1.45; p=0.14) and 5-year survival rate of 34% versus 31%, respectively) 
(26).  
Hence, conventionally fractionated platinum-based concurrent CRT starting within the 
first nine weeks after initial diagnosis (up to the third chemotherapy cycle) remains a 
mostly acceptable primary multimodal treatment protocol. Therefore, there is a clear 
interest of the multidisciplinary clinical community to optimize this multimodal concept 
regarding treatment efficacy and tolerability.   
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Since a randomized phase III study from Turrisi et al. was published in 1999, early 
concurrent hyperfractionated accelerated platinum-based CRT was established as a 
preferential treatment standard for LD SCLC (5, 7). The early start of thoracic irradiation 
with the first chemotherapy cycle was considered as an important pre-requisite. Almost 
20 years later, a randomized phase III study (CONVERT) demonstrated non-significant 
differences in long-term patient outcome (median overall survival of 30 versus 25 months 
(HR 1.18, 95% CI 0.95–1.45; p=0.14) and 5-year survival of 34% versus 31%) with 
hyperfractionated accelerated (analog Turrisi et al) versus conventional fractionated 
(once daily) concurrent CRT, starting with the second cycle of chemotherapy and 
reported historically best overall survival rates in both arms (26). However, the relevant 
difference between both landmark trials was a total dose of the thoracic irradiation in the 
once daily group (45 a 1.8 Gy versus 66 a 2.0 Gy in the Turrisi and CONVERT trials, 
respectively). Importantly, along the time period between these important studies, 
adoption of the Turrisi protocol in clinical practice has remained very low, especially in 
Europe (between 5-21% of cancer centers) (24, 25). The reasons for this was because 
of the significantly higher rates of acute severe toxicity (especially esophagitis) and higher 
logistic effort for the treating radiation oncology department. Hence, continuous 
optimization of conventionally fractionated CRT protocols was mostly a way to improve 
patient prognosis in non-metastatic SCLC. 
In the first work published in 2011, impact of treatment course of primary CRT on outcome 
in LD SCLC patients with poor initial performance status was analyzed (27). 149 patients 
with initial performance status WHO 2-3, histologically confirmed SCLC and 
comprehensively staged disease were allocated to primary multimodal therapy. In 24/149 
(16%) patients, definitive CRT could not be completed because of treatment- 
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related toxicity and further deterioration of patients’ general condition. The successful 
completion of primary multimodal treatment was the first factor significantly influencing  
patient prognosis (see Figure 1 ).  
 
 
Figure 1: Overall survival in LD SCLC patients with  poor initial performance 
status according to the completion of primary multi modal treatment (p< 0.005, 
log-rank test) 
In patients who could not complete CRT, the median survival time of 11.3 months was 
very disappointing and comparable with metastatic stage. Hence, further analysis of 
treatment-related factors was focused exclusively on the patient cohort who successfully 
completed initial therapy. 125/149 (84%) patients were identified. Importantly, the 
conventionally fractionated thoracic irradiation with a total dose of at least 50.0 Gy was 
delivered in all patients, whereas 13/125 (10%) patients were treated with less than four 
cycles of chemotherapy. Sequential and concurrent CRT, was applied in 74 (59%) and  
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51 (41%) patients, respectively. PCI was delivered only in complete responders to 
primary treatment. There was no difference in the objective response rate, progression-
free and overall survival in patients treated in the sequential or concurrent setting. 
However, the study identified an overall duration of CRT itself as a prognostic treatment-
related factor for both sequential and concurrent patient subgroups. Overall duration of 
CRT was the sole factor correlating with overall survival on uni- (p < 0.014) and 
multivariate (p < 0.025) analyses, respectively. Patients with short and dose-dense 
primary multimodal treatment achieved a significantly improved long-term outcome. 
Additionally, a trend to prolonged overall survival in patients who completed concurrent 
CRT was documented on the multivariate analysis (p = 0.072). Therefore, this study was 
the first reporting a prognostic role of the overall duration of primary multimodal treatment 
in LD SCLC patients with poor initial performance status. 
Four years later, a new investigation with the aim of exact evaluation of the impact of 
CRT schedule parameters on outcome in a real-life LD SCLC patient cohort from two 
university hospitals was conducted (28). In total, schedule parameters of the primary 
multimodal treatment were analyzed in 182 patients. Only 4% of patients were treated 
with early hyperfractionated accelerated concurrent CRT according to Turrisi et al (7). 
PCI was performed in patients with complete and partial remission after CRT. To better 
define the role of the concurrent treatment phase, a new parameter IST (interval of 
simultaneous treatment) was established. IST was assessed as a time interval, 
measured in days, when radiotherapy and chemotherapy for the primary thoracic disease 
were applied concurrently, including weekends and time between chemotherapy cycles. 
Definition of this parameter and its possible variations in the primary multimodal treatment 
course is illustrated in the Figure 2 . 
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Figure 2: Definition of interval of simultaneous tr eatment (IST) 
All 182 patients completed primary CRT: an absolute majority (96%) of patients were 
treated according to the conventional CRT protocol with total radiation dose of at least 
50 Gy (range: 50 – 66). Median duration of chemotherapy was 128 and 93 days in 
patients treated concurrently and sequentially, respectively; median duration of thoracic 
irradiation was 43 days. Several IST values (30, 35, 42 and 49 days) were reviewed. IST 
35 was supposed to be an optimal cut off for further analysis because this interval 
included at least two completed chemotherapy cycles and considered both the patients 
treated with accelerated (analogue Turrisi et al.) and conventional thoracic irradiation.  
According to the IST definition, 182 patients were divided as follows: IST 0 (sequential 
CRT) 111/182 (61%), IST > 0 and < 35 (short dose dense concurrent phase) 20/182 
(11%) and IST > 35 51/182 (28%) (prolonged concurrent phase) subgroups, respectively. 
Median survival of the entire cohort reached 534 days and did not differ significantly 
between patients treated in the concurrent or sequential setting (589 and 533 days, 
respectively). Nevertheless, in the analysis according to the IST values, the IST > 0 and 
< 35 subgroup showed a trend to prolonged overall survival with 1169 (95CI: 800 – 1538) 
days vs. 533 (95CI: 446 – 620) and 448 (95CI: 361 – 535) days in the IST 0 and IST > 
35 subgroups, respectively (p = 0.109) (see Figure 3 ).  
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Almost a doubling of the overall survival time compared with the rest of cohort was 
reached in patients treated with short dose dense concurrent CRT corresponding to the 
IST > 0 and > 35 days. In a further analysis of 71/182 (39%) patients treated exclusively 
with concurrent CRT, the overall survival benefit in the IST > 0 and < 35 subgroup 
reached significance on uni- (p = 0.021) and multivariate (p = 0.039, HR 0.38) analyses, 
respectively. Importantly, there was no registered survival benefit between patients who 
completed sequential (IST = 0) and prolonged concurrent phase CRT (IST > 35 days). 
 
 
Figure 3: Overall survival in patient subgroups def ined by IST 
Taken together, the present study determined that duration of the concurrent phase of 
primary multimodal treatment, namely IST, was associated with patient outcome and 
revealed a short dose-dense concurrent phase (IST > 0 and < 35 days) as an optimal  
value for the planning of definitive CRT. 
Subsequently, the next analysis evaluated an impact of the primary tumor response  
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after completion of CRT on patient outcome (29). The patient subgroups were defined 
according to the achieved remission status after primary multimodal treatment, e.g. 
complete vs. partial response vs. non-response (defined as stable and progressive  
disease) and compared with each other referring to the different survival parameters. 
Again, all 184 patients completed primary multimodal treatment and PCI was performed 
exclusively in the complete and partial responders. From the 184 analyzed patients who 
successfully completed primary multimodal treatment, 65 (35%), 77 (42%) and 37 (20%) 
demonstrated complete, partial remission and non-response, respectively. In 5 (3%) 
patients, remission status could not be validated. Median overall survival was 21.8 (95CI: 
18.6-25) vs. 14.9 (95CI: 11.7-18.2) vs. 11.5 (95CI: 8.9-15) months in the complete, partial 
and non-responders, respectively (p < 0.001) (see Figure 4 ). 
The same effect was observed for the time to progression and distant-metastasis-free 
survival. On multivariate analysis (after adjustment for other prognostic factors), patients 
who achieved a complete remission to primary multimodal treatment showed a 
significantly improved overall survival in comparison to non-responders and 
demonstrated a trend to improved time to progression (p = 0.1, HR 1.48) and distant- 
metastasis-free survival (p = 0.06, HR 1.63) compared to partial responders. 
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Figure 4: Overall survival in patient subgroups def ined by remission status after 
primary multimodal treatment  
Thus, this study revealed a significant correlation of achieved remission status of primary 
thoracic disease after CRT with patient survival and control of distant systemic disease. 
Especially important was the overall survival and distant control advantage documented 
in the complete compared to partial responders. 
Finally, an extensive retrospective follow-up analysis for the exact assessment of the 
timing of treatment failure (temporal distribution of recurrent disease) in LD SCLC 
patients after completion of CRT was carried out (30).  
The medical charts of LD SCLC patients who successfully completed primary multimodal 
treatment were reviewed. This temporal analysis of treatment failure demonstrated that 
disease recurrence including local, distant and intracranial relapse will occur in the first 
year after initial diagnosis in more than half of the treated patients.  
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Based on this finding, the study recommended an intensified follow-up at least in the first 
year after diagnosis with the possibility of early salvage treatment, also in asymptomatic 
patients. 
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Roengvoraphoj O, Eze C, Niyazi M, Li M, Hildebrandt G, Fietkau R,Belka C, Manapov 
F. Prognostic role of patient gender in limited-disease small-cell lung cancer treated with 
chemoradiotherapy. Strahlenther Onkol. 2017 Feb;193(2):150-155. [IF 2.459] 
 
 
 
 
 
Habilitationsschrift Dr. med. F. Manapov 
 
23 
 
 
Eze C, Roengvoraphoj O, Niyazi M, Hildebrandt G, Fietkau R, Belka C, Manapov F . 
Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a 
Real-life Limited-disease Small-cell Lung Cancer Patient Cohort Comprehensively 
Staged With Cranial Magnetic Resonance Imaging. Clin Lung Cancer. 2017  
Jul;18(4):e243-e249. [IF 4.204] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Habilitationsschrift Dr. med. F. Manapov 
 
24 
 
 
Because of the biology of SCLC as a highly aggressive tumor characterized by rapid 
growth and early metastatic dissemination, a special attention of clinicians must be 
focused on the incidence of intracranial metastases (1, 2, 4). At least 10% of subjects will 
be present with symptomatic BM at initial evaluation with the cumulative risk rising to 
more than 50% in the second year after initial diagnosis and up to 80% of subjects at 
autopsy. The reported rate of asymptomatic (occult) BM at initial diagnosis is considered 
higher and could rise to 24% of all patients evaluated by contrast-enhanced cranial 
magnetic resonance imaging (MRI) (3, 4). The brain is considered as a sanctuary site 
because the blood-brain barrier can serve as potential protection of intracranial 
metastases from cytotoxic agents. The aim of PCI in LD SCLC was proposed to 
overcome this protection effect. 
In 1999, a key meta-analysis from Aupérin et al. first demonstrated a significant decrease 
in the cumulative incidence of BM in SCLC complete responders after PCI (31). 
Importantly, the absolute majority of patients included in the study presented initially with 
LD. Moderate overall survival benefit (3-year survival rate: 20.7 versus 15.3% with and 
without PCI, respectively) was reported in the complete responders, regardless of 
whether they were treated with sequential CRT or chemotherapy alone.  
This meta-analysis included seven randomized trials with enrollment period from 1977 to 
1994. According to the enrollment time, comprehensive brain imaging based on contrast-
enhanced cranial MRI at initial diagnosis as well as after completion of primary 
multimodal treatment was not consecutively performed. The tumor re-staging after 
primary treatment also varied significantly between the trials.  
Respecting these relevant clinical uncertainties, a single-center study on the role of 
comprehensive brain imaging (serial contrast-enhanced cranial MRIs) in patients with  
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LD SCLC was conducted (32). We analyzed 105 consecutive LD SCLC patients treated 
with sequential and/or concurrent CRT. 40/105 (38%) patients achieved complete 
remission to primary multimodal treatment and were considered for PCI. Importantly, first 
contrast-enhanced cranial MRI was performed in all patients at initial diagnosis. A second 
MRI was scheduled exclusively in the forty complete responders immediately before PCI 
to exclude occult intracranial relapse (see Figure 1 ).  
 
 
Figure 5: Patient selection according to the outcom e of chemoradiotherapy  
All forty complete responders were neurologically asymptomatic at that time. Surprisingly, 
the study revealed asymptomatic BM in 13/40 (32.5%; 95% CI: 18-47%) asymptomatic 
patients. Furthermore, complete responders with occult BM demonstrated a significantly  
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worse long-term outcome compared with patients without pre-PCI detected BM (median 
overall survival and 1-year survival rate: 14 versus 26 months and 58.7 versus 92%, p = 
0.0001, respectively). The highly negative prognostic impact of intracranial involvement 
in SCLC also in spite of intensive multimodal treatment with cranial and thoracic CRT 
was confirmed in another small study (33).  
Taken together, this single-center study investigating the role of second contrast-
enhanced cranial MRI was the first demonstrating a significant prevalence of 
asymptomatic BM in LD SCLC complete responders immediately before PCI and 
providing evidence that a comprehensive brain imaging program, including first and 
second cranial MRI before and after primary treatment and immediately before PCI, could 
be an optimal detection tool for the exclusion of occult intracranial disease. 
Subsequently, a correlation between response of primary thoracic disease to applied 
CRT and duration of brain-metastasis-free survival in LD SCLC was investigated (34). 
125 LD SCLC patients who successfully completed multimodal treatment were analyzed. 
There was a significant difference in the incidence of metachronous intracranial relapse 
according to the achieved primary treatment response in the thorax. 50% (15/30 patients) 
of the metachronous BM occurred in the thoracic non-responders (stable disease and/or 
local progression) compared to 33 and 17% in the patients with complete and partial 
remission, respectively (p< 0.0001). Importantly, the duration of brain-metastasis-free 
survival was also significantly different in the patient subgroups according to the 
remission status of thoracic disease. The median time interval to development of BM was 
252, 298 and 567 days in the non-, partial and complete responders, respectively 
(p<0.0001). In the complete responders, application of PCI led to further prolongation of 
brain-metastasis-free survival (640 compared to 482 days in patients with and without  
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PCI, respectively (p = 0.047)). The study has also confirmed a dismal prognosis of SCLC 
patients with metachronous intracranial failure with only 2.6 months median survival time 
from diagnosis of brain relapse. Altogether, the main finding was a direct correlation 
between achieved primary intrathoracic tumor response and duration of brain-
metastasis-free survival as well as incidence of metachronous intracranial recurrence. 
Present results suggested that achieved response of primary tumor can further influence 
the course of SCLC disease and must be respected in clinical trials considering PCI and 
different consolidation protocols. Additionally, another study assessing the prognostic 
impact of the patient gender in LD SCLC, found a higher prevalence of metachronous 
BM in the male subgroup compared to females (36 vs 26%, respectively, p=0.03), 
although a small but significant difference in the rate of achieved partial remission to CRT 
was detected in women compared to men (48 versus 42%, p = 0.05) (35). Importantly, 
no difference in overall survival between male and female patients treated with PCI was 
found. 
To extend research on the potential mutual effect of achieved intra-thoracic treatment 
response and PCI on the patient prognosis in LD SCLC, clinical data were updated and 
a new study investigating the prognostic role of both factors in a real-life LD SCLC patient 
cohort comprehensively staged with contrast-enhanced cranial MRI was conducted (36). 
The flow-chart of this study is illustrated in the Figure 2 .  
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Figure 6: Study design  
From 184 consecutive LD SCLC patients treated in two university centers, 60% were 
men. Importantly, in 60 and 55% of patients involved, mediastinal lymph nodes and  
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clinical T3/T4-stage were found at initial diagnosis. Concurrent or sequential CRT was 
applied in 39% and 61% of patients, respectively. 71/184 (39%) patients with partial and 
complete remission after primary multimodal treatment did not demonstrate occult BM on 
second contrast-enhanced cranial MRI and were referred for PCI. Different survival 
parameters were compared between the PCI (71 patients) and non-PCI (113 patients) 
subgroups also according to the achieved remission status of the primary thoracic 
disease. There was moderate imbalance between the subgroups regarding patient 
gender, CRT mode and dose-intensity of the chemotherapy. Especially, different dose-
intensity of systemic treatment (8 versus 27% of patients treated with less than four 
chemotherapy cycles in the PCI- and non-PCI subgroups, respectively) could potentially 
have an impact on the long-term outcome. As expected, the incidence of metachronous 
BM was lower in the PCI (23%) compared to non-PCI (37%) subgroup. Furthermore, 
partial and complete responders treated with PCI demonstrated a significantly longer time 
to progression and overall survival compared to the therapy-responders without PCI and 
non-responders (see Table 1 ). 
 Partial and complete 
responders with PCI, 
months 
Partial and complete 
responders without 
PCI, months 
Non-responders, 
months 
Overall survival 26 (range 19.4 - 32.6) 14 (range 11.4 - 16.6) 9  
Time to progression 27  14.5 (range 9 - 19.9) 8.8 (range 7.7 -
9.9) 
 
Table 1: OS and PFS according to remission status a nd PCI 
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The overall survival plot demonstrated a remarkable long-term survival benefit of CRT 
responders treated with PCI, beginning early after completion of the primary multimodal 
treatment and sustained for more than 60 months (Figure 3 ).  
 
 
Figure 3: Overall survival in patient subgroups def ined by application of PCI and 
treatment response after CRT 
 
Importantly, the overall survival benefit was also confirmed on multivariate analysis after 
adjustment of other prognostic factors. In all, this study assessed an authentic 
prophylactic effect of PCI and confirmed a strong impact of the PCI versus non-PCI on 
patient long-term outcome in treatment responders to CRT. Additionally, the study 
pointed out a potential mutual effect of achieved remission of primary disease and PCI in 
the LD SCLC. 
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SUMMARY 
 
In summary, several consecutive studies in the field of definitive CRT in LD SCLC have 
resulted in the identification and characterization of the important treatment-related 
factors with significant impact on patient prognosis: 
The completeness of primary multimodal treatment in LD SCLC is of special importance. 
The patients who could not successfully complete CRT demonstrated very disappointing 
outcome which was comparable to metastatic disease.  
When considering primary multimodal treatment of thoracic disease, extra attention must 
be paid to the overall duration of the CRT itself. Short and dose-dense multimodal 
treatment was associated with significantly improved patient survival independent of CRT 
mode (concurrent and/or sequential). 
In patients treated with simultaneous CRT, a special focus must be made on the 
concurrent phase of multimodal treatment. An IST > 0 and < 35 days, as an optimal value 
to achieve the best long-term outcome, was recommended. 
An achievement of complete remission of primary thoracic disease after multimodal 
treatment is a relevant factor for patient prognosis because of improved time to 
progression and overall survival in complete versus partial responders. 
As a result of continuous research in this field, further treatment-related factors regarding 
application of PCI after completion of primary multimodal treatment in LD SCLC were 
described: 
Second contrast-enhanced cranial MRI after completion of CRT and immediately before 
PCI was established as a diagnostic tool and demonstrated significant prevalence of 
occult intracranial disease in LD SCLC complete responders. After exclusion of the  
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occult BM, a real authentic role of PCI on patient prognosis could be evaluated. This 
study has resulted in the incorporation of second contrast-enhanced cranial  
MRI immediately before PCI in the current international guidelines for SCLC (NCCN, 
ESMO). 
Subsequently, correlation between response of primary thoracic disease to multimodal 
treatment and duration of brain-metastasis-free survival was described. The study 
showed that incidence and temporal distribution of the metachronous intracranial relapse 
depended on the achieved thoracic remission status. Hence, remission of primary 
thoracic disease after CRT must be taken into consideration prior to planning of PCI and 
further consolidation treatment. 
The mutual prognostic role of both achieved intra-thoracic treatment response and PCI 
was confirmed in a real-life LD SCLC patient cohort comprehensively staged with 
contrast-enhanced cranial MRI. This data is of special importance because a significant 
survival advantage was confirmed in the partial and complete responders treated with 
PCI. 
In conclusion, an intensive follow-up, at least, in the first year after initial diagnosis was 
recommended because of the results of a retrospective study on temporal distribution of 
disease recurrence in LD SCLC. Also, the results of this follow-up study were included 
as a recommendation for patient surveillance in the current NCCN guidelines. 
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ABBREVIATIONS 
ALK   Anaplastic lymphoma kinase 
BM      Brain metastases 
CI   Confidence interval 
CRT   Chemoradiotherapy 
CT   Computed tomography 
ED   Extensive disease 
EGFR   Epidermal growth factor receptor 
ESMO   European Society for Medical Oncology 
PET/CT   Positron emission tomography with 2-deoxy-2-[ fluorine-18] fluoro-  
   D glucose integrated with computed tomography 
HR   Hazard ratio 
IST   interval of simultaneous treatment 
LD   Limited disease 
MRI   magnetic resonance imaging 
NCCN   National comprehensive cancer network 
PCI   Prophylactic cranial irradiation 
SCLC    Small-cell lung cancer 
SER   The start of any treatment until the end of radiotherapy 
TNM   Tumor, Node, Metastases 
UICC   Union international contre le cancer 
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